Key result
Oral fenoximone therapy in refractory NYHA class IV heart failure significantly increased cardiac index (p=0.0001) but lacked sustained clinical benefit and was associated with high mortality.
Why the study?
Does oral fenoximone improve hemodynamics and clinical outcomes in male patients with refractory NYHA class IV congestive heart failure?
Population
13 male patients with NYHA class IV congestive heart failure refractory to conventional therapy
Design
Case_series
Follow-up
mean 11 weeks (range 2 to 34)
Authors
Loading...
Suggests caution with oral fenoximone in refractory NYHA IV HF due to high mortality; leaves open need for randomized evaluation of hemodynamic support.
Does oral fenoximone improve hemodynamics and clinical outcomes in male patients with refractory NYHA class IV congestive heart failure?
p-value: p=0.0001
Oral fenoximone provides short-term hemodynamic benefits but is associated with high mortality and lack of sustained efficacy in refractory heart failure.
Shah et al. (1985) studied NYHA class IV congestive heart failure refractory to conventional therapy (n=13). Oral fenoximone was evaluated on Cardiac index and pulmonary capillary wedge pressure (p=0.0001). Oral fenoximone therapy in refractory NYHA class IV heart failure significantly increased cardiac index (p=0.0001) but lacked sustained clinical benefit and was associated with high mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: